Revolution Medicines has successfully closed an upsized public offering of common stock and pre-funded warrants, including the full exercise of the underwriters' option to purchase additional shares. The offering is part of a broader trend in the biotech sector, which also includes Janux Therapeutics announcing the closure of its own underwritten public offering, generating total gross proceeds of $402.5 million. This amount consists of an upsized offering of $350 million plus a full exercise of a $52.5 million greenshoe option. Additionally, Amgen has made a significant investment of $1 billion in cancer drug development, collaborating with AstraZeneca and Daiichi on their cancer drug initiatives. The total financing activity in the sector includes follow-on offerings exceeding $1.2 billion from Revolution and Janux, along with a $250 million private investment in public equity (PIPE) for Olema to support a Phase III study of a combination therapy.